Lin28b is a biomarker of survival and an actionable therapeutic target in pancreatic cancer patients:
- LIN28B has been shown to play an important role in development, stem cell biology, and tumorigenesis in a variety of solid tumors;
- Pancreatic cancer, hepatocellular cancer, colon cancer, multiple myeloma, lung cancer, neuroblastoma and others.
- Increased expression of Lin28b has been shown to correlate with poor survival in PDAC patients (see Figure A above)
- It has been shown that Lin28b is required for the growth and survival of SIRTlow PDAC
- Knocking down Lin28b with both small hairpin RNA (shRNA) and small interfering RNA (siRNA) resulted in potent suppression of cell proliferation and tumor sphere formation
- Knocking down Lin28b inhibited in vivo xenograft growth (See Figure B above)
- Knockdown of Lin28b led to both G1 cell-cycle arrest and induction of apoptosis